In agreement with these observations, other studies showed in CTCs, from advanced NSCLC patients, the expression of oncogene drivers such as EML4-ALK and mutant EGFR associated with the presence of mesenchymal markers [30, 31]. This evidence concerns the gene EGFR and non-small cell lung carcinoma.